So-Young International Inc. (SY) 株式分析

企業概要

So-Young International Inc. operates an online platform dedicated to delivering consumption healthcare services within the People's Republic of China, primarily through its So-Young Mobile App. The company facilitates user access to medical aesthetic knowledge, community support networks, and reservation options for treatments administered by medical professionals. This enterprise functions within the Healthcare sector, specifically classified under the Health Information Services industry, which implies a focus on digital health solutions and information dissemination rather than direct pharmaceutical manufacturing. The company's current market capitalization stands at $287.62M, while its trailing twelve-month revenue reaches $1.52B, though specific employee count data is not publicly disclosed. These financial metrics suggest a significant operational scale relative to typical pure-play health information service providers, indicating substantial market penetration and revenue generation capabilities despite the absence of reported headcount figures.

財務健全性

The company reported a revenue of $1.52B for the trailing twelve months, yet it recorded a net income of $-242,300,992 and an EBITDA of $-220,548,992 during the same period. The substantial disparity between the $1.52B revenue and the negative net income reveals a heavy cost structure where operating expenses significantly exceed gross profits, resulting in a loss before interest, taxes, depreciation, and amortization. While free cash flow data is not available, the company holds a cash balance of $871.68M against total debt of $299.71M, suggesting a robust liquidity position despite the earnings deficit. The debt-to-equity ratio is recorded at 17.96, which indicates a highly leveraged balance sheet where liabilities substantially outweigh equity, contrasting with the conservative nature of the high cash reserves. The current ratio stands at 1.89, indicating that the company possesses $1.89 in current assets for every $1 of current liabilities, which points to adequate short-term liquidity to meet immediate obligations. Return on Equity is -13.6% and Return on Assets is -6.2%, metrics that reveal that management has not yet generated positive returns on the capital invested or the assets utilized, reflecting the ongoing challenges in converting revenue into profit.

バリュエーション評価

The trailing twelve-month P/E ratio is not available due to the company's net loss, whereas the forward P/E ratio is listed as -11.76, implying that the market currently expects earnings to remain negative or is pricing in significant future losses. The price-to-book ratio is 1.28, indicating that the market values the company at 28% above its book value, which may reflect potential future growth expectations or intangible asset premiums despite current profitability issues. Alternative valuation metrics such as the price-to-sales ratio of 0.19 and an EV/EBITDA of 1.07 suggest that the stock is priced at a fraction of its sales, which often occurs when investors anticipate a turnaround in profitability. The 52-week high is $6.28 and the 52-week low is $0.67, placing the current trading range within a wide band that reflects high volatility typical of small-cap healthcare stocks. The beta value of 2.17 indicates that the stock price is expected to be 117% more volatile than the broader market, highlighting the inherent risks associated with this specific equity instrument.

Growth & Income

Revenue growth year-over-year is recorded at 24.8%, while earnings growth is not available due to the company's persistent net loss position. This divergence, where revenue expands significantly while earnings remain negative, implies that top-line expansion is occurring without a corresponding improvement in the bottom line, likely driven by the high operating costs mentioned in the financial health analysis. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders, effectively choosing to reinvest any available cash flow or retained earnings into business operations rather than providing income to investors. The overall growth and income profile characterizes So-Young International Inc. as a high-revenue growth company that is currently unprofitable and does not provide dividend income, relying entirely on future operational improvements to potentially generate returns for its equity holders.